Search results for " Failure"

showing 10 items of 1828 documents

Head-to-head comparison of contemporary heart failure risk scores.

2021

Altres ajuts: acords transformatius de la UAB Aims: Several heart failure (HF) web-based risk scores are currently used in clinical practice. Currently, we lack head-to-head comparison of the accuracy of risk scores. This study aimed to assess correlation and mortality prediction performance of Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC-HF) risk score, which includes clinical variables + medications; Seattle Heart Failure Model (SHFM), which includes clinical variables + treatments + analytes; PARADIGM Risk of Events and Death in the Contemporary Treatment of Heart Failure (PREDICT-HF) and Barcelona Bio-Heart Failure (BCN-Bio-HF) risk calculator, which also include biomarke…

medicine.medical_specialtyCalibration (statistics)Head to headHeart failureSpearman's rank correlation coefficientRisk AssessmentCorrelationRisk FactorsInternal medicineNatriuretic Peptide BrainmedicineRisk modelsHumansOverall performanceMortalityNatriuretic PeptidesHeart FailureFramingham Risk Scorebusiness.industrymedicine.diseasePrognosisRisk predictionPeptide FragmentsClinical PracticeHeart failureCardiology and Cardiovascular MedicinebusinessBiomarkersEuropean journal of heart failureReferences
researchProduct

Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study

2021

Summary Background Trans-arterial chemoembolization (TACE) is one first-line option therapy for patients with hepatocellular carcinoma (HCC) not suitable for surgical resection. Aims We evaluated the effects of sunitinib plus doxorubicin-TACE on bleeding or liver failure. Methods Seventy-eight patients with HCC were included in this randomized, double-blind study. They received one to three TACE plus either sunitinib or placebo four weeks out of six for one year. The occurrence of severe bleeding or liver failure was assessed during the week after the TACE. The safety and survival outcomes were evaluated. Results No bleeding complication was reported. One and two liver failures were respect…

medicine.medical_specialtyCarcinoma HepatocellularNeutropeniaurologic and male genital diseasesPlaceboPlacebo groupGastroenterology03 medical and health sciences0302 clinical medicineInternal medicineSunitinibmedicineHumansChemoembolization TherapeuticHepatologybusiness.industrySunitinibLiver NeoplasmsGastroenterologyLiver failuremedicine.diseaseAcute toxicityTreatment Outcome030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyDose reductionbusinessLiver Failuremedicine.drugClinics and Research in Hepatology and Gastroenterology
researchProduct

BIOELECTRICAL IMPEDANCE ANALYSIS FOR PREDICTION OF HOSPITAL ADMISSION DUE TO CARDIAC DECOMPENSATION IN AMBULATORY HEART FAILURE: A FOLLOW-UP STUDY

2008

medicine.medical_specialtyCardiac decompensationbusiness.industryHeart failureHospital admissionAmbulatoryInternal MedicineFollow up studiesmedicineIntensive care medicinebusinessmedicine.diseaseBioelectrical impedance analysisEuropean Journal of Internal Medicine
researchProduct

Measuring physical activity with activity monitors in patients with heart failure: from literature to practice. A position paper from the Committee o…

2020

The aims of this paper were to provide an overview of available activity monitors used in research in patients with heart failure and to identify the key criteria in the selection of the most appropriate activity monitor for collecting, reporting, and analysing physical activity in heart failure research. This study was conducted in three parts. First, the literature was systematically reviewed to identify physical activity concepts and activity monitors used in heart failure research. Second, an additional scoping literature search for validation of these activity monitors was conducted. Third, the most appropriate criteria in the selection of activity monitors were identified. Nine activi…

medicine.medical_specialtyCardiologyPhysical activity610 Medicine & healthHeart failureFitness Trackers030204 cardiovascular system & hematologyMedical and Health Sciences2705 Cardiology and Cardiovascular MedicineExercise Capacity03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitation[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicineHumansCardiac and Cardiovascular SystemsIn patientExercise physiologyAssociation (psychology)Set (psychology)ExerciseMonitoring PhysiologicHeart FailureKardiologiPhysical activitybusiness.industryPhysical activity; Activity monitor; Motion sensor; Accelerometer; Heart failuremedicine.diseaseActivity monitor[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemAccelerometerHeart failure10209 Clinic for CardiologyMotion sensorPosition paperPosition PaperHuman medicineClinical MedicineCardiology and Cardiovascular MedicineRaw databusinessEuropean Journal of Heart Failure
researchProduct

Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without typ…

2020

Abstract Aims The EMPERIAL (Effect of EMPagliflozin on ExeRcise ability and HF symptoms In patients with chronic heArt faiLure) trials evaluated the effects of empagliflozin on exercise ability and patient-reported outcomes in heart failure (HF) with reduced and preserved ejection fraction (EF), with and without type 2 diabetes (T2D), reporting, for the first time, the effects of sodium-glucose co-transporter-2 inhibition in HF with preserved EF (HFpEF). Methods and results HF patients with reduced EF (HFrEF) (≤40%, N = 312, EMPERIAL-Reduced) or preserved EF (>40%, N = 315, EMPERIAL-Preserved), with and without T2D, were randomized to empagliflozin 10 mg or placebo for 12 weeks. The …

medicine.medical_specialtyCardiomyopathyType 2 diabetes030204 cardiovascular system & hematologyPlacebo03 medical and health sciences0302 clinical medicineGlucosidesInternal medicinemedicineClinical endpointEmpagliflozinHumans030212 general & internal medicineBenzhydryl CompoundsHeart FailureEjection fractionSurrogate endpointbusiness.industryStroke Volumemedicine.diseaseDiabetes Mellitus Type 2Heart failureCardiologyCardiology and Cardiovascular MedicinebusinessEuropean heart journal
researchProduct

Levosimendan in the treatment of patients with acute cardiac conditions: an expert opinion of the Association of Intensive Cardiac Care of the Polish…

2020

Levosimendan is a new inodilator which involves 3 main mechanisms: increases the calcium sensitivity of cardiomyocytes, acts as a vasodilator due to the opening of potassium channels, and has a cardioprotective effect. Levosimendan is mainly used in the treatment of acute decompensated heart failure (class IIb recommendation according to the European Society of Cardiology guidelines). However, numerous clinical trials indicate the validity of repeated infusions of levosimendan in patients with stable heart failure as a bridge therapy to heart transplantation, and in patients with accompanying right ventricular heart failure and pulmonary hypertension. Due to the complex mechanism of action,…

medicine.medical_specialtyCardiotonic AgentsAcute decompensated heart failureinotropic agentsacute heart failuremedicine.medical_treatment030204 cardiovascular system & hematologylevosimendan03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansinodilatorAdverse effectExpert TestimonySimendanHeart FailureHeart transplantationbusiness.industryHydrazonesLevosimendanmedicine.diseasePulmonary hypertensionCardiac surgeryPyridazinesClinical trialHeart failurechronic advanced systolic heart failureCardiologyPolandCardiology and Cardiovascular Medicinebusinessmedicine.drugKardiologia Polska
researchProduct

Special Considerations for Antihypertensive Agents in Dialysis Patients

2010

Hypertension is present in most patients with end-stage renal disease and likely contributes to the premature cardiovascular disease in dialysis patients. Previous practice guidelines have recommended that, in patients on chronic dialysis, blood pressure (BP) should be reduced below 130/80 mm Hg. This is based on opinions but not strong evidence, since no concrete information exists about which BP values should be the parameter to follow and which should be the target BP values. The majority of the antihypertensive agents can be used in this population, but the pharmacokinetics altered by the impaired kidney function and dialyzability influence the appropriate dosage as well as the time and…

medicine.medical_specialtyCardiotonic AgentsHypertension RenalCombination therapyMetabolic Clearance Ratemedicine.drug_classVasodilator Agentsmedicine.medical_treatmentAdrenergic beta-AntagonistsPopulationAngiotensin-Converting Enzyme InhibitorsCardiotonic AgentsRenal DialysisInternal medicinemedicineHumansDrug InteractionsDiureticseducationAntihypertensive drugAntihypertensive AgentsDialysisRandomized Controlled Trials as Topiceducation.field_of_studybusiness.industryHematologyGeneral MedicineCalcium Channel Blockersmedicine.diseaseEndocrinologyBlood pressureCardiovascular DiseasesNephrologyPractice Guidelines as TopicPolypharmacyKidney Failure ChronicDrug Therapy CombinationHemodialysisbusinessAngiotensin II Type 1 Receptor BlockersKidney diseaseBlood Purification
researchProduct

Cancer and Infective Endocarditis: Characteristics and Prognostic Impact

2021

Background: The interplay between cancer and IE has become of increasing interest. This study sought to assess the prevalence, baseline characteristics, management, and outcomes of IE cancer patients in the ESC EORP EURO-ENDO registry.Methods: Three thousand and eighty-five patients with IE were identified based on the ESC 2015 criteria. Three hundred and fifty-nine (11.6%) IE cancer patients were compared to 2,726 (88.4%) cancer-free IE patients.Results: In cancer patients, IE was mostly community-acquired (74.8%). The most frequently identified microorganisms were S. aureus (25.4%) and Enterococci (23.8%). The most frequent complications were acute renal failure (25.9%), embolic events (2…

medicine.medical_specialtyCardiovascular Medicineregistryvalve diseasesurgeryInternal medicinemedicinecancerDiseases of the circulatory (Cardiovascular) systemOriginal Researchbusiness.industryinfective endocarditisCancermedicine.diseaseCardiac surgery[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieBaseline characteristicsHeart failureInfective endocarditisRC666-701oncologyCohort[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieObservational studyCardiology and Cardiovascular MedicinebusinessValve diseasecardiac surgeryFrontiers in Cardiovascular Medicine
researchProduct

Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analys…

2017

People with severe mental illness (SMI) – schizophrenia, bipolar disorder and major depressive disorder – appear at risk for cardiovascular disease (CVD), but a comprehensive meta-analysis is lacking. We conducted a large-scale meta-analysis assessing the prevalence and incidence of CVD; coronary heart disease; stroke, transient ischemic attack or cerebrovascular disease; congestive heart failure; peripheral vascular disease; and CVD-related death in SMI patients (N=3,211,768) versus controls (N=113,383,368) (92 studies). The pooled CVD prevalence in SMI patients (mean age 50 years) was 9.9% (95% CI: 7.4-13.3). Adjusting for a median of seven confounders, patients had significantly higher o…

medicine.medical_specialtyCardiovascular disease; bipolar disorder; cerebrovascular disease; congestive heart failure; coronary heart disease; major depression; premature mortality; schizophrenia; severe mental illness03 medical and health sciences0302 clinical medicinesevere mental illnessMedicineCardiovascular disease severe mental illness schizophrenia bipolar disorder major depression coronary heart disease cerebrovascular disease congestive heart failure premature mortalitycoronary heart diseasePsychiatrybipolar disorderFramingham Risk Scorebusiness.industryVascular diseaseIncidence (epidemiology)Hazard ratioCorrectionOdds ratiomedicine.diseaseCardiovascular disease030227 psychiatrycerebrovascular diseaseschizophreniaPsychiatry and Mental healthcongestive heart failurepremature mortalityHeart failureMajor depressive disorderPshychiatric Mental Healthbusinessmajor depressionBody mass index030217 neurology & neurosurgery
researchProduct

Ultrasound (US) guided central venous catheterization of internal jugular vein on over 65-year-old patients versus blind technique.

2004

Background and Objectives Performing a central venous catheterization (CVC) on older patients for long-term central intravenous therapy could be a very important procedure. It could be associated with a high incidence of related complications, especially on over 65-year-old, high risk, selected patients. Methods The authors analyzed the results of 72 central venous CVC of internal jugular vein performed on over 65-year-old patients with ultrasound (US) guide from January 1998 to April 2003. Results The average performing time was 4 min, with 98.7% of success, 0% of major complications, and 4.1% of minor complications (one mild vagal hypotension and two catheter dislocation). Conclusions The…

medicine.medical_specialtyCatheterization Central VenousVenous catheterizationbusiness.industryIncidence (epidemiology)UltrasoundGeneral MedicineSurgeryCathetermedicine.anatomical_structureOncologyAnesthesiaJugular veinmedicineHumansSurgeryEquipment FailureHypotensionJugular VeinsbusinessVeinLower limbs venous ultrasonographyInternal jugular veinUltrasonography InterventionalAgedJournal of surgical oncology
researchProduct